- Home
- ORMP vs NGEN Comparison
ORMP vs NGEN Comparison
Compare ORMP & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORMP | NGEN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 197.5M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | ORMP | NGEN |
|---|---|---|
| Price | $4.32 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 171.6K | ★ 654.8K |
| Earning Date | 05-14-2026 | 04-02-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.90 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.58 |
| 52 Week High | $5.19 | $5.93 |
Technical Indicators
Market Signals| Indicator | ORMP | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 41.91 |
| Support Level | $3.90 | $1.59 |
| Resistance Level | $5.10 | $2.22 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 79.24 | 44.23 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.